Last Updated: November 13, 2026

Chartwell Company Profile

« Back to Dashboard

What is the competitive landscape for CHARTWELL

CHARTWELL has six hundred and fifty-four approved drugs.

There are four tentative approvals on CHARTWELL drugs.

Summary for Chartwell

US Patents:	0
Tradenames:	429
Ingredients:	400
NDAs:	654

Drugs and US Patents for Chartwell

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Molecular	ACETAZOLAMIDE	acetazolamide	TABLET;ORAL	084840-001	Approved Prior to Jan 1, 1982	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Injectable	PROPRANOLOL HYDROCHLORIDE	propranolol hydrochloride	INJECTABLE;INJECTION	075792-001	Aug 29, 2000		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Molecular	DOXYCYCLINE HYCLATE	doxycycline hyclate	TABLET;ORAL	065277-001	Nov 10, 2005	AB	RX	No	Yes		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	PIRFENIDONE	pirfenidone	TABLET;ORAL	212403-002	Aug 23, 2023		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	CLOPIDOGREL BISULFATE	clopidogrel bisulfate	TABLET;ORAL	202266-002	Nov 20, 2012		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Molecular	OLANZAPINE	olanzapine	TABLET;ORAL	203333-003	Mar 15, 2016	AB	RX	No	No		⤷ Start Trial				⤷ Start Trial
Chartwell Rx	METOCLOPRAMIDE HYDROCHLORIDE	metoclopramide hydrochloride	TABLET;ORAL	074478-002	Oct 5, 1995		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Chartwell

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Chartwell Rx	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997	6,258,830	⤷ Start Trial
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-008	Approved Prior to Jan 1, 1982	3,491,093	⤷ Start Trial
Chartwell Molecular	MYKROX	metolazone	TABLET;ORAL	019532-001	Oct 30, 1987	4,517,179	⤷ Start Trial
Chartwell Rx	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	5,089,509	⤷ Start Trial
Chartwell Rx	MOBAN	molindone hydrochloride	TABLET;ORAL	017111-005	Approved Prior to Jan 1, 1982	3,491,093	⤷ Start Trial
Chartwell Rx	TAZORAC	tazarotene	GEL;TOPICAL	020600-002	Jun 13, 1997	6,258,830	⤷ Start Trial
Chartwell Rx	VELTIN	clindamycin phosphate; tretinoin	GEL;TOPICAL	050803-001	Jul 16, 2010	9,492,384	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.